PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026

Hemophilia A and B are rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, and are characterized by the failure of blood to form normal clots after damage to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing through adulthood. However, the burden on patients and their families of maintaining the prophylactic treatment schedule is high.

Traditionally, the hemophilia market has been dominated by short-acting rFVIII or FIX concentrates. However, in recent years the hemophilia market has become increasingly competitive due to the approval of extended half-life products that can reduce the burden associated with prophylaxis. These improvements have mainly benefited hemophilia B patients, while a substantial unmet need remains for hemophilia A patients and patients with inhibitors who do not respond to standard treatments.

The hemophilia pipeline activity is strong and includes two candidates, Roche’s emicizumab (ACE-910) and Alnylam’s fitusiran, which do not exploit a replacement strategy but target different effectors of the coagulation cascade and are expected to cause a paradigm shift in the treatment of the disease.

Key Questions Answered

What are the key drivers behind the increasing uptake and market penetration of the long-acting factor concentrates in hemophilia A and B, since their approval in 2014, and what is the trend in the use of long-acting factors in the forecast period?

The hemophilia market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?

What impact will the approval of Roche’s emicizumab have on the hemophilia market? What will the drug’s peak sales be, and why?

Scope

Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.

Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Amunix

Apitope

Aptevo Therapeutics

Bayer

Baxter

Baxalta

Biogen

BioMarin

Bioverativ

Catalyst Biosciences

Chugai

CSL Behring

Dimension Therapeutics

LFB

Novo Nordisk

Octapharma

Opko Biologics

Pfizer

Revo ...

Amunix

Apitope

Aptevo Therapeutics

Bayer

Baxter

Baxalta

Biogen

BioMarin

Bioverativ

Catalyst Biosciences

Chugai

CSL Behring

Dimension Therapeutics

LFB

Novo Nordisk

Octapharma

Opko Biologics

Pfizer

Revo Biologics

Roche/Genentech

Sangamo Therapeutics

Shire

Spark Therapeutics

uniQure

Xenetic Biosciences

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Sales for Hemophilia ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Sales for Hemophilia A and B Recombinant Therapies by Region, 2016–2026

2.2 Long-Acting rFVIIIs Have Not Lived Up to Expectations

2.3 Inhibitor Segment to Devalue Post-Alternative Coagulation Promoter Launch

2.4 Roche’s Emicizumab to Radically Impact Hemophilia A and Inhibitor Segments

2.5 Treatment Cost to Remain a Major Unmet Need

2.6 New Comers to Take Over Market Space From Established Companies

2.7 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification

4.3 Symptoms

4.3.1 Hemophilia A and B

4.3.2 Inhibitors

4.4 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Diagnosed Prevalent Cases

5.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

5.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors

5.5 Epidemiological Forecast for Hemophilia A (2016–2026)

5.5.1 Diagnosed Prevalent Cases of Hemophilia A

5.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A

5.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A

5.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity

5.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors

5.6 Epidemiological Forecast for Hemophilia B (2016–2026)

5.6.1 Diagnosed Prevalent Cases of Hemophilia B

5.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B

5.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B

5.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity

5.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors

5.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016–2026)

5.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

5.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

5.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

5.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

5.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

5.8 Discussion

5.8.1 Epidemiological Forecast Insight

5.8.2 Limitations of the Analysis

5.8.3 Strengths of the Analysis

6 Disease Management

6.1 Treatment Overview

6.1.1 Treatment Guidelines

6.1.2 Clinical Practice

6.2 US

6.2.1 Clinical Practice

6.3 France

6.3.1 Clinical Practice

6.4 Germany

6.4.1 Clinical Practice

6.5 Italy

6.5.1 Clinical Practice

6.6 Spain

6.6.1 Clinical Practice

6.7 UK

6.7.1 Clinical Practice

6.8 Japan

6.8.1 Clinical Practice

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Hemophilia A

7.2.1 Short Acting rFVIII

7.2.2 Long Acting rFVIII

7.2.3 Plasma-Derived FVIII Concentrates

7.2.4 Desmopressin Acetate

7.3 Product Profiles – Hemophilia B

7.3.1 Short Acting rFIX

7.3.2 Long Acting FIX

7.3.3 Plasma-Derived FIX Concentrates

7.4 Product Profiles – Hemophilia A and B with Inhibitors

7.4.1 NovoSeven RT (Eptacog Alfa)

7.4.2 Feiba NF (Activated Prothrombin Complex Concentrate)

8 Unmet Needs and Opportunities

8.1 Overview

8.2 Reduction in Risk of Inhibitor Development in Previously Untreated Patients

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 More Effective Treatments for Patients with Inhibitors

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Longer-Lasting Agents and More Convenient Administration Routes

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Treatments to Cure the Disease

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Decreasing the Costs Associated with Prophylaxis

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

8.7 Individualized Prophylaxis

8.7.1 Unmet Need

8.7.2 Gap Analysis

8.7.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Late-Stage Development Candidates – Hemophilia A

9.2.1 BAY 94-9027 (Damoctocog Alfa Pegol)

9.2.2 N8-GP (Turoctocog Alfa Pegol)

9.2.3 Emicizumab (ACE-910, RG-6013)

9.2.4 Fitusiran (ALN-AT3, SAR-439774)

9.3 Late-Stage Development Candidates – Hemophilia B

9.4 Late-Stage Development Candidates – Hemophilia A and B Patients with Inhibitors

9.4.1 LR-769 (rhFVIIa)

9.4.2 Obizur (Susoctocog Alfa)

9.4.3 CSL-689 (rVIIa-FP)

9.4.4 BAX-817 (rFVIIa BI)

9.5 Promising Approaches in Early-Stage Development

9.5.1 Alternative Coagulation Promoters – Tissue Factor Pathway Inhibitors

9.5.2 Gene Therapies

9.5.3 Replacement Strategies

9.5.4 Strategies to Prevent and Manage Inhibitors

9.5.5 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Bayer

10.3.2 Bioverativ

10.3.3 CSL Behring

10.3.4 Novo Nordisk

10.3.5 Pfizer

10.3.6 Roche

10.3.7 Shire

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Market

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers – 5EU

11.3.4 Drivers and Barriers – France

11.3.5 Drivers and Barriers – Germany

11.3.6 Drivers and Barriers – Italy

11.3.7 Drivers and Barriers – Spain

11.3.8 Drivers and Barriers – UK

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.4 Forecasting Methodology

12.4.1 Diagnosed Hemophilia Patients

12.4.2 Percent Drug-Treated Patients

12.4.3 Drugs Included in Each Therapeutic Class

12.4.4 Launch and Patent Expiry Dates

12.4.5 General Pricing Assumptions

12.4.6 Individual Drug Assumptions

12.4.7 Pricing of Pipeline Agents

12.5 Primary Research – KOLs Interviewed for this Report

12.6 Primary Research – Prescriber Survey

12.7 Real-World Data

12.8 About the Authors

12.8.1 Analyst

12.8.2 Reviewer

12.8.3 Therapy Area Director

12.8.4 Epidemiologists

12.8.5 Reviewers

12.8.6 Global Director of Therapy Analysis and Epidemiology

12.8.7 Global Head and EVP of Healthcare Operations and Strategy

12.9 About GlobalData

12.10 Contact Us

12.11 Disclaimer

List of tables

Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2016–2026

Table 2: Classification of Hemophilia A and B

Table 3 ...

Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2016–2026

Table 2: Classification of Hemophilia A and B

Table 3: Symptoms of Hemophilia A and B

Table 4: Relationship of Bleeding Severity with Clotting Factor Level.

Table 5: Comorbidities for Hemophilia

Table 6: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016–2026.

Table 7: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016–2026.

Table 8: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016–2026.

Table 9: 7MM Treatment Guidelines for Hemophilia

Table 10: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2016

Table 11: Definition of Therapeutic Protocols in Hemophilia

Table 12: Country Profile — US, 2016

Table 13: Country Profile — France, 2016

Table 14: Country Profile — Germany, 2016

Table 15: Country Profile — Italy, 2016

Table 16: Country Profile — Spain, 2016

Table 17: Country Profile — UK, 2016

Table 18: Country Profile — Japan, 2016

Table 19: Leading Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2017

Table 20: Product Profile – Recombinate

Table 21: Summary of the Results of the Pivotal Trial of Recombinate

Table 22: Recombinate SWOT Analysis, 2017

Table 23: Product Profile – Kogenate FS

Table 24: Summary of the Results from the Trial that Led to the Approval of Kogenate FS

Table 25: Summary of the Results from the Trial that Studies Kogenate FS in Pediatric Prophylaxis

Table 26: Kogenate FS SWOT Analysis, 2017

Table 27: Product Profile –Helixate FS

Table 28: Helixate FS SWOT Analysis, 2017

Table 29: Product Profile – Advate

Table 30: Summary of the Results from the Part 2 Phase II/III Pivotal Trial of Advate

Table 31: Summary of the Results from the Phase IV Prophylaxis Study of Advate

Table 32: Advate SWOT Analysis, 2017

Table 33: Product Profile – Kovaltry

Table 34: Summary of the LEOPOLD I and II Trials of Kovaltry

Table 35: Summary of the LEOPOLD Kids Trial of Kovaltry

Table 36: Kovaltry SWOT Analysis, 2017

Table 37: Product Profile – Xyntha/ReFacto AF

Table 38: Summary of the Pivotal Trial of Xyntha

Table 39: Xyntha/ReFacto AF SWOT Analysis, 2017

Table 40: Product Profile – NovoEight

Table 41: Summary of the Results of The Guardian 1 Trial of NovoEight

Table 42: Summary of the Results of The Guardian 3 Trial of NovoEight

Table 43: NovoEight SWOT Analysis, 2017

Table 44: Product Profile – Nuwiq

Table 45: Summary of the Results from the GENA-01, GENA-08, and GENA-03 Trials of Nuwiq

Table 46: Nuwiq SWOT Analysis, 2017

Table 47: Product Profile – Eloctate

Table 48: Summary of the Results of the A-LONG Trial of Eloctate

Table 49: Eloctate SWOT Analysis, 2017

Table 50: Product Profile – Adynovate

Table 51: Summary of the Results of the PROLONG-ATE Trial of Adynovate

Table 52: Summary of the Results of the BAX855 Pediatric Trial of Adynovate

Table 53: Adynovate SWOT Analysis, 2017

Table 54: Product Profile – Afstyla

Table 55: Summary of the Results of the AFFINITY and Pediatric Trials of Afstyla

Table 56: Afstyla SWOT Analysis, 2017

Table 57: Marketed Plasma-Derived Replacement Therapies for Hemophilia A Patients, 2017

Table 58: Product Profile – BeneFIX

Table 59: Summary of the Results of the Phase III Trial of BeneFIX

Table 60: Summary of the Results that Proved the Effectiveness of BeneFIX as Prophylaxis Regimen

Table 61: Summary of the Results of the Phase III BeneFIX 1010 Study

Table 62: BeneFIX SWOT Analysis, 2017

Table 63: Product Profile – Rixubis

Table 64: Summary of the Results of the Pivotal Trial of Rixubis

Table 65: Summary of the Results of the Pediatric Trial of Rixubis

Table 66: Rixubis SWOT Analysis, 2017

Table 67: Product Profile – IXinity

Table 68: Summary of the Results of the Pivotal Trial of IXinity

Table 69: IXinity SWOT Analysis, 2017

Table 70: Product Profile – Alprolix

Table 71: Summary of the Results of the B-LONG Trial of Alprolix

Table 72: Summary of the Results of the Kids B-Long Trial of Alprolix

Table 73: Alprolix SWOT Analysis, 2017

Table 74: Product Profile – Idelvion

Table 75: Summary of the Results of the CSL654_3001 Trial of Idelvion

Table 76: Summary of the Results of the CSL654_3002 Trial of Idelvion

Table 77: Idelvion SWOT Analysis, 2017

Table 78: Product Profile – Rebynin

Table 79: Results of the Paradigm 2 Trial of Rebynin

Table 80: Results of the Pediatric Paradigm 5 Trial of Rebynin

Table 81: Rebynin SWOT Analysis, 2017

Table 82: Marketed Plasma-Derived Replacement Therapies for Hemophilia B Patients, 2017

Table 83: Product Profile – NovoSeven RT

Table 84: Summary of the Results of the Phase III Trial of NovoSeven

Table 85: NovoSeven RT SWOT Analysis, 2017

Table 86: Product Profile – Feiba NF

Table 87: Summary of the Results of the PROOF Trial of Feiba NF

Table 88: Feiba NF SWOT Analysis, 2017

Table 89: Unmet Needs and Opportunities in Hemophilia

Table 90: Product Profile – BAY 94-9027

Table 91: Efficacy of BAY 94-9027 in the PROTECT VIII study

Table 92: BAY 94-9027 SWOT Analysis, 2017

Table 93: Product Profile – N8-GP

Table 94: Efficacy of N8-GP in the Pathfinder 2 and 5Trials

Table 95: N8-GP SWOT Analysis, 2017

Table 96: Product Profile – Emicizumab

Table 97: Efficacy of Emicizumab in a Japanese Phase I/II Study

Table 98: Emicizumab SWOT Analysis, 2016

Table 99: Product Profile – Fitusiran

Table 100 : Efficacy of Fitusiran in the Part-D Phase I Study

Table 101: Fitusiran SWOT Analysis, 2017

Table 102: Product Profile – LR-769

Table 103: LR-769 SWOT Analysis, 2017

Table 104: Product Profile – Obizur

Table 105: Obizur SWOT Analysis, 2017

Table 106: Product Profile – CSL-689

Table 107: CSL-689 SWOT Analysis, 2017

Table 108: Product Profile – BAX-817

Table 109: BAX-817 SWOT Analysis, 2017

Table 110: TFPI inhibitors – Early-Stage Pipeline, 2017

Table 111: Hemophilia A and B Gene Therapies – Early-Stage Pipeline, 2017

Table 112: Hemophilia A and B Recombinant Replacement Therapies – Early-Stage Pipeline, 2017

Table 113: Drugs in Development for Hemophilia, 2016

Table 114: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2016–2026

Table 115: Bayer’s Hemophilia Portfolio Assessment, 2015

Table 116: Bayer SWOT Analysis, 2017

Table 117: Bioverativ/Sobi’s Hemophilia Portfolio Assessment, 2017

Table 118: Bioverativ SWOT Analysis, 2017

Table 119: CSL Behring’s Hemophilia Recombinant Portfolio Assessment, 2017

Table 120: CSL Behring SWOT Analysis, 2017

Table 121: Novo Nordisk’s Hemophilia Recombinant Portfolio Assessment, 2017

Table 122: Novo Nordisk SWOT Analysis, 2017

Table 123: Pfizer’s Hemophilia Recombinant Portfolio Assessment, 2017

Table 124: Pfizer SWOT Analysis, 2017

Table 125: Roche’s Hemophilia Recombinant Portfolio Assessment, 2017

Table 126: Roche SWOT Analysis, 2017

Table 127: Shire’s Hemophilia Recombinant Portfolio Assessment, 2017

Table 128: Shire SWOT Analysis, 2017

Table 129: Global Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 130: Key Events Impacting Sales for Hemophilia A and B in the US, 2016–2026

Table 131: US Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 132: Key Events Impacting Sales for Hemophilia A and B Therapeutics in the 5EU, 2016–2026

Table 133: 5EU Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 134: French Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 135: German Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 136: Italian Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 137: Spanish Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 138: UK Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 139: Key Events Impacting Sales for Hemophilia A and B in Japan, 2016–2026

Table 140: Japanese Hemophilia A and B Market – Drivers and Barriers, 2016–2026

Table 141: Key Launch Dates

Table 142: Key Historical and Projected Patent Expiry Dates

Table 143: Average Body Weight Across the 7MM

Table 144: Average Cost of Therapy of Plasma-Derived FVIII Concentrates in the 7MM

Table 145: Average Cost of Therapy of Recombinate in the 7MM

Table 146: Average Cost of Therapy of Kogenate FS in the 7MM

Table 147: Average Cost of Therapy of Helixate FS in the 7MM

Table 148: Average Cost of Therapy of Advate in the 7MM

Table 149: Average Cost of Therapy of Kovaltry in the 7MM

Table 150: Average Cost of Therapy of Xyntha in the 7MM

Table 151: Average Cost of Therapy of NovoEight in the 7MM

Table 152: Average Cost of Therapy of Nuwiq in the 7MM

Table 153: Average Cost of Therapy of Eloctate in the 7MM

Table 154: Average Cost of Therapy of Adynovate in the 7MM

Table 155: Average Cost of Therapy of Afstyla in the 7MM

Table 156: Average Cost of Therapy of Plasma-derived FIX Concentrates in the 7MM

Table 157: Average Cost of Therapy of BeneFIX in the 7MM

Table 158: Average Cost of Therapy of Rixubis in the 7MM

Table 159: Average Cost of Therapy of IXinity in the 7MM

Table 160: Average Cost of Therapy of Alprolix in the 7MM

Table 161: Average Cost of Therapy of Idelvion in the 7MM

Table 162: Average Cost of Therapy of NovoSeven in the 7MM

Table 163: Average Cost of Therapy of Feiba in the 7MM

Table 164: Average Cost of Therapy of DDAVP in the 7MM

Table 165: Physicians Surveyed

List of figures

Figure 1: Sales for Hemophilia A and B Therapeutics by Drug Class, 2016–2026

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents, 2016–2026

Figure ...

Figure 1: Sales for Hemophilia A and B Therapeutics by Drug Class, 2016–2026

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents, 2016–2026

Figure 3: Key Company Portfolio Positioning in Hemophilia A and B, 2016–2026

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016

Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016

Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016

Figure 11: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016

Figure 12: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016

Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016

Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016

Figure 15: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016

Figure 16: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016

Figure 17: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016

Figure 18: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016

Figure 19: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016

Figure 20: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016

Figure 21: Treatment Flowchart for Severe Patients with Inhibitors

Figure 22: Competitive Assessment of Late-Stage Pipeline Agents, 2016–2026

Figure 23: Overview of the Development Pipeline in Hemophilia, 2016–2026

Figure 24: Hemophilia A – Phase III Pipeline, 2017

Figure 25: BAY94-9027’s Clinical Development in Hemophilia A

Figure 26: Clinical and Commercial Positioning of BAY94-9027

Figure 27: N8-GP’s Clinical Development in Hemophilia A

Figure 28: Clinical and Commercial Positioning of N8-GP

Figure 29: Emicizumab’s Clinical Development in Hemophilia A

Figure 30: Clinical and Commercial Positioning of Emicizumab

Figure 31: Clinical and Commercial Positioning of Fitusiran

Figure 32: Hemophilia A and B with Inhibitors – Phase III Pipeline, 2017

Figure 33: LR-769’s Clinical Development in Patients with Inhibitors

Figure 34: Clinical and Commercial Positioning of LR-769

Figure 35: Obizur’s Clinical Development in Patients with Inhibitors

Figure 36: Clinical and Commercial Positioning of Obizur

Figure 37: CSL-689’s Clinical Development in Patients with Inhibitors

Figure 38: Clinical and Commercial Positioning of CSL-689

Figure 39: Clinical and Commercial Positioning of BAX-817

Figure 40: Company Portfolio Analysis in Hemophilia A and B, 2016–2026

Figure 41: Global Sales of Hemophilia Therapeutics by Company, 2016–2026

Figure 42: Global Sales for Hemophilia A and B by Drug Class, 2016–2026

Figure 43: Global Sales for Hemophilia A and B Therapeutics by Region, 2016–2026

Figure 44: Sales for Hemophilia A and B Therapeutics in the US by Drug Class, 2016–2026

Figure 45: Sales for Hemophilia A and B Therapeutics in the 5EU by Drug Class, 2016–2026

Figure 46: Sales for Hemophilia A and B Therapeutics in the 5EU by Country, 2016–2026

Figure 47: Sales for Hemophilia A and B Therapeutics in Japan by Drug Class, 2016–2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports